/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED
STATES/
VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSXV: NUMI), a company
creating an ecosystem of health solutions centred around developing
and supporting the safe, evidence-based, accessible use of
psychedelic-assisted psychotherapy, is pleased to announce that the
TSX Venture Exchange ("TSXV") has accepted for listing the
9,200,000 warrants (the "Warrants") issued pursuant to the
Company's previously announced prospectus offering that closed on
September 10, 2020.
The Warrants will be listed for trading on the TSXV under the
symbol "NUMI.WT" effective at market open on Monday, September 21, 2020.
Each Warrant entitles the holder thereof to acquire one common
share of the Company at an exercise price of $0.35 until September 10,
2022. The Warrants were issued pursuant to, and are governed
by, a warrant indenture between the Company and Computershare Trust
Company of Canada dated
September 10, 2020.
About Numinus
Numinus is a Vancouver-based
health care company creating an ecosystem of health solutions
centred around developing and supporting the safe, evidence-based,
accessible use of psychedelic-assisted therapies. Numinus'
ecosystem units include Numinus Bioscience, Numinus R&D, and
Numinus Health. Each unit is undertaking distinct, synergistic
initiatives to hasten legal, for-profit psychedelic-assisted
therapy models in Canada and
position Numinus as a trusted industry leader for the eventual
regulated rollout of these therapies once available. Numinus
Bioscience includes a 7,000 square foot research and testing
laboratory as well as numerous Health Canada licenses (through its
wholly-owned subsidiary Salvation Botanicals) including a cannabis
testing licence used for sustainable revenue to support the
company's psychedelic efforts. The company holds a dealers licence
which allows it to import, export, possess, and test MDMA,
psilocybin, psilocin, DMT and mescaline. Numinus is the only
publicly listed company in Canada
to be issued a Health Canada license to produce and extract
psilocybin from mushrooms. These licences will allow Numinus to
support the growing number of studies on the potential benefits of
psychedelic therapies through research projects, product
development, and the supply and distribution of these substances.
Numinus R&D leverages established relationships to position the
Company for partnerships to host studies, develop medical and
therapeutic protocols, and influence regulatory approval. Numinus
Heath is dedicated to delivering therapies that enhance and
supplement existing options for people wanting lasting physical,
mental and emotional health — with psychedelic treatments at its
core when approved for therapeutic and research use. For more
information, visit www.numinus.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.
Payton Nyquvest
President, Chief Executive Officer and Chair
Further information about the Company is available under its
profile on the SEDAR website, www.sedar.com, and on the Company's
website.
SOURCE Numinus Wellness Inc.